| pubmed-article:14574332 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:14574332 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:14574332 | lifeskim:mentions | umls-concept:C0026764 | lld:lifeskim |
| pubmed-article:14574332 | lifeskim:mentions | umls-concept:C0021013 | lld:lifeskim |
| pubmed-article:14574332 | lifeskim:mentions | umls-concept:C0042196 | lld:lifeskim |
| pubmed-article:14574332 | lifeskim:mentions | umls-concept:C0677908 | lld:lifeskim |
| pubmed-article:14574332 | lifeskim:mentions | umls-concept:C1328050 | lld:lifeskim |
| pubmed-article:14574332 | lifeskim:mentions | umls-concept:C1517942 | lld:lifeskim |
| pubmed-article:14574332 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:14574332 | pubmed:dateCreated | 2003-12-17 | lld:pubmed |
| pubmed-article:14574332 | pubmed:abstractText | The aim of this work was to evaluate the long-term immunological and clinical impact of idiotype (Id) vaccination in multiple myeloma (MM) patients in first remission after high-dose chemotherapy. A total of 15 patients received a series of subcutaneous (s.c.) injections of autologous Id, conjugated to keyhole limpet hemocyanin (KLH) and in association with low doses of GM-CSF. The median duration of follow-up was 110 months from diagnosis. The vaccine induced immune responses that lasted almost 2 years after the end of treatment. Antibody responses included anti-KLH IgM and IgG (90% of patients), anti-KLH IgE (30%), anti-GM-CSF IgG (20%), anti-Id IgG (20%), and anti-Id IgE (30%). Id-specific delayed type hypersensitivity skin tests were positive in 85% of tested patients. Following vaccination, a progressive recovery of T-cell receptor (TCR) diversity was observed and the loss of oligoclonality was significantly correlated with the remission duration. Although Id/KLH conjugates did not eliminate the residual tumor burden, the median progression-free survival, and overall survival were 40 and 82 months, respectively. A retrospective case-matched analysis showed similar results in patients treated with IFN-alpha alone or in association with steroids. This vaccine formulation can overcome Id-specific immune tolerance by inducing clinical responses that are worthy of further investigation. | lld:pubmed |
| pubmed-article:14574332 | pubmed:language | eng | lld:pubmed |
| pubmed-article:14574332 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14574332 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:14574332 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14574332 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14574332 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14574332 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14574332 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14574332 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14574332 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14574332 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14574332 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14574332 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14574332 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:14574332 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:14574332 | pubmed:issn | 0887-6924 | lld:pubmed |
| pubmed-article:14574332 | pubmed:author | pubmed-author:PileriAA | lld:pubmed |
| pubmed-article:14574332 | pubmed:author | pubmed-author:BoccadoroMM | lld:pubmed |
| pubmed-article:14574332 | pubmed:author | pubmed-author:CosciaMM | lld:pubmed |
| pubmed-article:14574332 | pubmed:author | pubmed-author:Di BelloCC | lld:pubmed |
| pubmed-article:14574332 | pubmed:author | pubmed-author:MarianiSS | lld:pubmed |
| pubmed-article:14574332 | pubmed:author | pubmed-author:MassaiaMM | lld:pubmed |
| pubmed-article:14574332 | pubmed:author | pubmed-author:BattaglioSS | lld:pubmed |
| pubmed-article:14574332 | pubmed:author | pubmed-author:FioreFF | lld:pubmed |
| pubmed-article:14574332 | pubmed:author | pubmed-author:FogliettaMM | lld:pubmed |
| pubmed-article:14574332 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:14574332 | pubmed:volume | 18 | lld:pubmed |
| pubmed-article:14574332 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:14574332 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:14574332 | pubmed:pagination | 139-45 | lld:pubmed |
| pubmed-article:14574332 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:14574332 | pubmed:meshHeading | pubmed-meshheading:14574332... | lld:pubmed |
| pubmed-article:14574332 | pubmed:meshHeading | pubmed-meshheading:14574332... | lld:pubmed |
| pubmed-article:14574332 | pubmed:meshHeading | pubmed-meshheading:14574332... | lld:pubmed |
| pubmed-article:14574332 | pubmed:meshHeading | pubmed-meshheading:14574332... | lld:pubmed |
| pubmed-article:14574332 | pubmed:meshHeading | pubmed-meshheading:14574332... | lld:pubmed |
| pubmed-article:14574332 | pubmed:meshHeading | pubmed-meshheading:14574332... | lld:pubmed |
| pubmed-article:14574332 | pubmed:meshHeading | pubmed-meshheading:14574332... | lld:pubmed |
| pubmed-article:14574332 | pubmed:meshHeading | pubmed-meshheading:14574332... | lld:pubmed |
| pubmed-article:14574332 | pubmed:meshHeading | pubmed-meshheading:14574332... | lld:pubmed |
| pubmed-article:14574332 | pubmed:meshHeading | pubmed-meshheading:14574332... | lld:pubmed |
| pubmed-article:14574332 | pubmed:meshHeading | pubmed-meshheading:14574332... | lld:pubmed |
| pubmed-article:14574332 | pubmed:meshHeading | pubmed-meshheading:14574332... | lld:pubmed |
| pubmed-article:14574332 | pubmed:meshHeading | pubmed-meshheading:14574332... | lld:pubmed |
| pubmed-article:14574332 | pubmed:meshHeading | pubmed-meshheading:14574332... | lld:pubmed |
| pubmed-article:14574332 | pubmed:meshHeading | pubmed-meshheading:14574332... | lld:pubmed |
| pubmed-article:14574332 | pubmed:meshHeading | pubmed-meshheading:14574332... | lld:pubmed |
| pubmed-article:14574332 | pubmed:meshHeading | pubmed-meshheading:14574332... | lld:pubmed |
| pubmed-article:14574332 | pubmed:meshHeading | pubmed-meshheading:14574332... | lld:pubmed |
| pubmed-article:14574332 | pubmed:meshHeading | pubmed-meshheading:14574332... | lld:pubmed |
| pubmed-article:14574332 | pubmed:meshHeading | pubmed-meshheading:14574332... | lld:pubmed |
| pubmed-article:14574332 | pubmed:meshHeading | pubmed-meshheading:14574332... | lld:pubmed |
| pubmed-article:14574332 | pubmed:meshHeading | pubmed-meshheading:14574332... | lld:pubmed |
| pubmed-article:14574332 | pubmed:meshHeading | pubmed-meshheading:14574332... | lld:pubmed |
| pubmed-article:14574332 | pubmed:meshHeading | pubmed-meshheading:14574332... | lld:pubmed |
| pubmed-article:14574332 | pubmed:meshHeading | pubmed-meshheading:14574332... | lld:pubmed |
| pubmed-article:14574332 | pubmed:meshHeading | pubmed-meshheading:14574332... | lld:pubmed |
| pubmed-article:14574332 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:14574332 | pubmed:articleTitle | Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. | lld:pubmed |
| pubmed-article:14574332 | pubmed:affiliation | Centro di Ricerca in Medicina Sperimentale, Ospedale San Giovanni Battista, Torino, Italy. | lld:pubmed |
| pubmed-article:14574332 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:14574332 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14574332 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14574332 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14574332 | lld:pubmed |
